Sign in →

Test ID COGMF Acute Myeloid Leukemia (AML), Children’s Oncology Group Enrollment Testing, FISH, Varies


Advisory Information


This test is only performed on specimens from pediatric patients being considered for enrollment in a Children's Oncology Group (COG) protocol. For all other patients, order AMLF / Acute Myeloid Leukemia (AML), FISH, Varies.

 

For children in whom disease relapse or a secondary myeloid neoplasm is a concern and enrollment in a new COG protocol is being considered; order COGBM / Chromosome Analysis, Hematologic Disorders, Children’s Oncology Group Enrollment Testing, Bone Marrow.



Shipping Instructions


Advise Express Mail or equivalent if not on courier service.



Necessary Information


1. Provide a reason for referral with each specimen, as well as flow cytometry and/or a bone marrow pathology report and Children's Oncology Group (COG) protocol number. The laboratory will not reject testing if this information is not provided, but appropriate testing and interpretation may be compromised or delayed.

 2. If a child has received an opposite sex bone marrow transplant prior to specimen collection for this protocol, convey this information to the laboratory.



Specimen Required


Submit only 1 of the following specimens:

 

Preferred:

Specimen Type: Bone marrow

Container/Tube: Green top (sodium heparin)

Specimen Volume: 1 to 2 mL

Collection Instructions:

Invert several times to mix bone marrow.

 

Acceptable:

Specimen Type: Blood

Container/Tube: Green top (sodium heparin)

Specimen Volume: 6 mL

Collection Instructions:

Invert several times to mix blood.


Useful For

Evaluation of pediatric bone marrow and peripheral blood specimens by FISH probe analysis for classic rearrangements and chromosomal copy number changes associated with acute myeloid leukemia (AML) in patients being considered for enrolment in Children’s Oncology Group (COG) clinical trials and research protocols.

Highlights

Cytogenetic testing is important for the diagnostic and prognostic classification of pediatric neoplasia and it is a critical element for the enrollment of children into clinical trials affiliated with the Children’s Oncology Group (COG). For over 25 years, the Mayo Clinic Genomics Laboratory has served as one of a select number of laboratories in the United States approved by the COG for the conventional chromosome analysis and FISH analysis of pediatric bone marrow, peripheral blood, and tissue specimens. All enrollment-required elements of cytogenetic testing will be electronically submitted by the Mayo Clinic Genomics Laboratory within the guidelines of COG.

Reflex Tests

Test ID Reporting Name Available Separately Always Performed
_PBCT Probe, +2 No, (Bill Only) No
_PADD Probe, +1 No, (Bill Only) No
_PB02 Probe, +2 No, (Bill Only) No
_PB03 Probe, +3 No, (Bill Only) No
_IL25 Interphases, <25 No, (Bill Only) No
_I099 Interphases, 25-99 No, (Bill Only) No
_I300 Interphases, >=100 No, (Bill Only) No

Testing Algorithm

This test is only performed on specimens from pediatric patients who are candidates for enrollment in Children’s Oncology Group clinical trials and research protocols.

 

Indicate the subtype, as well as, which abnormalities need to be investigated from the following profile:

t(8;21), [M2], RUNX1T1/RUNX1

t(15;17), [M3], PML/RARA

11p15.4 rearrangement, NUP98

11q23 rearrangement, [M0-M7], MLL (KMT2A)

inv(16), [M4, Eos], MYH11/CBFB

+8, [M0-M7], D8Z2/MYC

t(6;9), [M2,M4], DEK/NUP214

inv(3) or t(3;3), [M1,2,4,6,7], RPN1/MECOM

t(8;16), [M4,M5], MYST3/CREBBP

t(3;5)(q25.32;q35.1), MLF1/NPM1

t(1;22), [M7], RBM15/MKL1*

-5/5q-, D5S630/EGR1

-7/7q-, D7S486/D7Z1

13q-, D13S319/LAMP1

17p-, TP53/D17Z1

20q-, D20S108/20qter

t(9;22), BCR/ABL1

 

*The RBM15/MKL1 probe set will only be used to test patients with a suspected or confirmed diagnosis of M7 or to confirm a t(1;22) identified by chromosome analysis.

 

-When NUP98 rearrangement is identified, reflex testing using the HOXA9/NUP98 probe set will be performed to identify a potential t(7;11)(p15;p15.4).

-When a MLL (KMT2A) rearrangement is identified, reflex testing will be performed to identify the translocation partner. Probes include identification of t(4;11)(q21;q23) AFF1/MLL, t(6;11)(q27;q23) MLLT4/MLL, t(9;11)(p22;q23) MLLT3/MLL, t(10;11)(p13;q23) MLLT10/MLL, t(11;16)(q23;p13.3) MLL/CREBBP, t(11;19)(q23;p13.1) MLL/ELL, or t(11;19)(q23;p13.3) MLL/MLLT1.

-When 3 copies of MECOM are observed with no fusion with RPN1, reflex testing using the MECOM/RUNX1 probe set will be performed to identify a potential t(3;21)(q26.2;q22) rearrangement.

-When 3 copies of RPN1 are observed with no fusion with MECOM, reflex testing using the PRDM16/RPN1 probe set will be performed to identify a potential t(1;3)(p36;q21).

 

The following testing algorithm is recommended for patients with acute myeloid leukemia (AML):

-At diagnosis, AML FISH panel and/or conventional chromosome studies COGBM / Chromosome Analysis, Hematologic Disorders, Children’s Oncology Group Enrollment Testing, Bone Marrow should be performed. If there is limited specimen available, only the COGMF / Acute Myeloid Leukemia (AML), FISH, Children’s Oncology Group Enrollment Testing, Blood and Bone Marrow test will be performed.--If this test is ordered and the laboratory is informed that the patient is not on a COG protocol, this test will be canceled and automatically reordered by the laboratory as AMLF / Acute Myeloid Leukemia (AML), FISH, Varies.

 

See Acute Promyelocytic Leukemia: Guideline to Diagnosis and Follow-up in Special Instructions

Method Name

Fluorescence In Situ Hybridization (FISH)

Reporting Name

COG, AML, FISH

Specimen Type

Varies

Specimen Minimum Volume

Blood: 2 mL
Bone Marrow: 1 mL

Specimen Stability Information

Specimen Type Temperature Time
Varies Ambient (preferred)
  Refrigerated 

Reference Values

An interpretive report will be provided.

Day(s) and Time(s) Performed

Samples processed Monday through Sunday. Results reported Monday through Friday, 8 a.m.-5 p.m. CST.

Performing Laboratory

Mayo Clinic Laboratories in Rochester

Test Classification

This test was developed using an analyte specific reagent. Its performance characteristics were determined by Mayo Clinic in a manner consistent with CLIA requirements. This test has not been cleared or approved by the U.S. Food and Drug Administration.

CPT Code Information

88271 x 2, 88291-DNA probe, each (first probe set), Interpretation and report

88271 x 2-DNA probe, each; each additional probe set (if appropriate)

88271-DNA probe, each; coverage for sets containing 3 probes (if appropriate)

88271 x 2-DNA probe, each; coverage for sets containing 4 probes (if appropriate)

88271 x 3-DNA probe, each; coverage for sets containing 5 probes (if appropriate)

88274 w/modifier 52-Interphase in situ hybridization, <25 cells, each probe set (if appropriate)

88274-Interphase in situ hybridization, 25 to 99 cells, each probe set (if appropriate)

88275-Interphase in situ hybridization, 100 to 300 cells, each probe set (if appropriate)

LOINC Code Information

Test ID Test Order Name Order LOINC Value
COGMF COG, AML, FISH In Process

 

Result ID Test Result Name Result LOINC Value
602276 Result Summary 50397-9
602277 Interpretation 69965-2
602278 Result Table 36908-2
602279 Result 62356-1
GC013 Reason for Referral 42349-1
GC014 Specimen 31208-2
602281 Source 31208-2
602282 Method 85069-3
602283 Additional Information 48767-8
602284 Disclaimer 62364-5
602285 Released By 18771-6

NY State Approved

No